---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-043023"
form_type: "8-K"
ticker: "OGN"
cik: "0001821825"
company_name: "Organon & Co."
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-23T00:57:23.864008+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Organon cuts dividend 93% to $0.08/yr; Q1 revenue down 7%, adj EPS $1.02

## Summary
- Q1 revenue $1.513B, -7% as-reported (-4% ex-FX); GAAP EPS $0.33, non-GAAP adj EPS $1.02.
- Board declared quarterly dividend $0.02/share (vs prior $0.28), payable June 12 to holders of record May 12.
- Women's Health +10% as-reported (+12% ex-FX) helped by Nexplanon; Biosimilars -17%; Established Brands -11%.
- Vtama on track for $150M full-year revenue; affirms 2025 guidance, expects >$900M FCF before one-time costs.
- Net income $87M, Adjusted EBITDA $484M (32% margin); company prioritizes deleveraging to net leverage <4.0x by year-end.

## SEC filing metadata
- accession: 0001104659-25-043023
- form_type: 8-K
- ticker: OGN
- cik: 0001821825
- company_name: Organon & Co.
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821825/000110465925043023/0001104659-25-043023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821825/000110465925043023/tm2513730d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-043023
- JSON: https://secwatch.observer/filing/0001104659-25-043023.json
- Plain text: https://secwatch.observer/filing/0001104659-25-043023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.